Liraglutide. A prominent example of successful molecular design is liraglutide (FDA-approved in 2010 as Victoza® for T2DM and in 2014 as Saxenda®, a GLP-1 analog with a fatty acid modification with a 16-carbon palmitic acid side chain linked by γ-glutamic acid that enables reversible binding to plasma albumin [80]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.